Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Evolus Inc (NQ: EOLS ) 12.31 +0.35 (+2.93%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 363,726 Open 12.19 Bid (Size) 11.63 (1) Ask (Size) 12.68 (1) Prev. Close 11.96 Today's Range 11.82 - 12.35 52wk Range 7.110 - 15.43 Shares Outstanding 54,576,156 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Evolus to Report Second Quarter Financial Results on July 31, 2024 July 17, 2024 From Evolus Via Business Wire Evolus Announces Appointment of Albert G. White III to Board of Directors July 01, 2024 From Evolus Via Business Wire Performance YTD +23.22% +23.22% 1 Month +16.68% +16.68% 3 Month +5.03% +5.03% 6 Month +1.82% +1.82% 1 Year +70.74% +70.74% More News Read More Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products June 24, 2024 From Evolus Via Business Wire Evolus: Chiseling Away At The Aesthetic Market May 25, 2024 Via Talk Markets Recap: Evolus Q4 Earnings March 07, 2024 Via Benzinga Earnings Outlook For Evolus March 06, 2024 Via Benzinga Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain June 12, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Evolus Via Business Wire Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting May 20, 2024 From Evolus Via Business Wire Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit May 15, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Evolus Via Business Wire Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year May 10, 2024 From Evolus, Inc. Via Business Wire EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Evolus Reports First Quarter 2024 Results and Provides Business Update May 07, 2024 From Evolus Via Business Wire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday May 02, 2024 Via InvestorPlace Evolus to Report First Quarter Financial Results on May 7, 2024 April 23, 2024 From Evolus Via Business Wire Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® April 17, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 12, 2024 From Evolus Via Business Wire Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference March 26, 2024 From Evolus Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session March 21, 2024 Via Benzinga Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock March 11, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From Evolus Via Business Wire EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 March 07, 2024 Via InvestorPlace Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance March 07, 2024 From Evolus Via Business Wire Earnings Scheduled For March 7, 2024 March 07, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
